Figure 4
From: Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent
Characterization of cancer cell killing and loss of client proteins by hybrid Antp-TPR peptide. (A) HEK293T and T47D cells treated with (+) or without (-) Antp-TPR peptide (68 μM) were analyzed after 24 h by dual-color flow cytometry for annexin V (left and middle lane panels) or caspase 3 and 7 (right lane panels) labeling in the green channel, and propidium iodide (PI) staining in the red channel as described in the Materials and Methods section. The percentage of cells in each quadrant is indicated, and the experiments were performed twice with similar results. (B) Loss of Hsp90 client proteins. T47D cells were incubated with Antp-TPR peptide (68 μM) for 48 h and analyzed by Western blotting with the indicated antibodies. (C) Western-blot analysis of Hsp90, Hsp70, and survivin expression in the normal and cancer cell lines HEK293T, Caki-1, BXPC3, T47D, and A549. Cell extracts from these cell lines were examined for protein expression by Western-blot analysis. β-actin was used as the loading control.